Parmax Pharma Limited announced unaudited standalone earnings results for the third quarter and nine months ended December 31, 2018. For the quarter, the company reported revenue from operations of INR 18,686,906 million against INR 25,785,127 million a year ago. Total income was INR 18,754,164 million against INR 25,831,009 million a year ago. Loss for the period was INR 2,914,375 million against profit of INR 369,029 million a year ago. Basic loss per share was INR 0.78 against earnings per share of INR 0.10 a year ago. For nine months, the company reported revenue from operations of INR 87,865,033 million against INR 87,423,921 million a year ago. Total income was INR 88,019,201 million against INR 87,715,054 million a year ago. Loss for the period was INR 7,845,000 million against INR 2,823,258 million a year ago. Basic loss per share was INR 2.10 against INR 0.75 a year ago.